A Peek Into The Market Before The Trading Starts
Pre-open movers US stock futures are lower this morning, as investors are awaiting new-home sales data. Futures for the Dow Jones Industrial Average dropped 19 points to 12,843.00 and S&P 500 index futures fell 3.30 points to 1,394.10. Nasdaq 100 futures declined 6.25 points to 2,635.00.
A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.21%, London's FTSE 100 Index dropped 0.25%, French CAC 40 Index declined 0.40% and German DAX 30 index fell 0.15%.
Asian markets ended lower, with Japan's Nikkei Stock Average dropping 1.22%, China's Shanghai Composite dropping 0.89% and Australia's S&P/ASX 200 falling 0.24%. Hong Kong's Hang Seng Index declined 0.62%.
Broker Recommendation Analysts at Piper Jaffray downgraded Windstream (NASDAQ: WIN) from “neutral” to “underweight.” The target price for Windstream has been lowered from $8 to $6.50.
Windstream shares gained 0.72% to $8.37 in after-hours trading.
- Toll Brothers (NYSE: TOL) recently purchased 692 acres in Montgomery County, the largest land contract for the national home builder since entering the Houston market in 2009. To read the full news, click here.
- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). To read the full news, click here.
- Curis (NASDAQ: CRIS) today announced that it has licensed from Genentech, a member of the Roche Group, (OTC: RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. To read the full news, click here.
- Forest Laboratories, (NYSE: FRX) and Gedeon Richter Plc. Announced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. To read the full news, click here.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.